Molecular Cancer Therapeutics | American Association for Cancer Research

Skip Nav Destination

Current Issue

Volume 22,

Issue 6

1 June 2023

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

6.009

SUBMIT TO JOURNAL

Featured Articles

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Qianhui Yi, et al.

Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death

Rita A. Avelar, et al.

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer

Bruno de Paula, et al.

Trending - Altmetric

The article titled, JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling, has an Alt Metric Attention Score of 9. Click to see more of this article's metrics.

Read the article titled, JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling

Last mentioned on Thursday June 1 2023

The article titled, The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth, has an Alt Metric Attention Score of 9. Click to see more of this article's metrics.

Read the article titled, The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Last mentioned on Thursday June 1 2023

The article titled, Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models, has an Alt Metric Attention Score of 12. Click to see more of this article's metrics.

Read the article titled, Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Last mentioned on Thursday June 1 2023

The article titled, IMiDs Augment CD3-Bispecific Antibody–Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production, has an Alt Metric Attention Score of 1. Click to see more of this article's metrics.

Read the article titled, IMiDs Augment CD3-Bispecific Antibody–Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production

Last mentioned on Wednesday May 31 2023

The article titled, Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers., has an Alt Metric Attention Score of 0.25. Click to see more of this article's metrics.

Read the article titled, Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers.

Last mentioned on Thursday June 1 2023

Latest
Most Read
Most Cited

3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability

Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors

Identification of a First-in-Class Small-Molecule Inhibitor of the EIF4E-RBM38 Complex That Enhances Wild-type TP53 Protein Translation for Tumor Growth Suppression

Targeting Glutamine Metabolism with a Novel Na⁺/K⁺-ATPase Inhibitor RX108 in Hepatocellular Carcinoma

Tweets by MCT_AACR

About the Journal

Editor-in-Chief

Impact Factor

Featured Articles

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer

Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer

Trending - Altmetric

AACR Journals

This Feature Is Available To Subscribers Only